News
VRCA
5.62
+9.98%
0.51
Weekly Report: what happened at VRCA last week (0406-0410)?
Weekly Report · 1d ago
Verrica late-breaking Phase 2 VP-315 data suggests abscopal effect in basal cell carcinoma
Reuters · 4d ago
Verrica Pharmaceuticals Reveals Acceptance Of A Late-breaking Abstract Reporting Phase 2 Exploratory Data Of VP-315; Data To Be Presented At The Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Benzinga · 4d ago
VERRICA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT HIGHLIGHTING POTENTIAL ABSCOPAL EFFECT OF VP-315 FOR THE TREATMENT OF BASAL CELL CARCINOMA AT THE UPCOMING 2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING
Reuters · 4d ago
Verrica Pharma CEO to present at Needham Virtual Healthcare Conference
Reuters · 04/06 12:02
Weekly Report: what happened at VRCA last week (0330-0403)?
Weekly Report · 04/06 09:24
Weekly Report: what happened at VRCA last week (0323-0327)?
Weekly Report · 03/30 09:24
Weekly Report: what happened at VRCA last week (0316-0320)?
Weekly Report · 03/23 09:23
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
Barchart · 03/20 18:42
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Barchart · 03/20 08:09
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Barchart · 03/19 13:15
Weekly Report: what happened at VRCA last week (0309-0313)?
Weekly Report · 03/16 09:23
Verrica Pharma Q4 And FY25 Revenue Improves; Plans Second Phase 3 Program For VP-102 In Mid 2026
NASDAQ · 03/12 05:39
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR)
TipRanks · 03/11 19:40
Verrica Pharmaceuticals: Focused Ycanth Rollout and Underpenetrated Pediatric Market Drive Attractive Risk‑Reward and Support Buy Rating
TipRanks · 03/11 16:05
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand
Reuters · 03/11 12:10
Verrica Pharmaceuticals Non-GAAP EPS of -$1.24 misses by $0.82, revenue of $35.58M beats by $0.58M
Seeking Alpha · 03/11 12:09
Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)
TipRanks · 03/11 12:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/11 12:06
Verrica FY 2025 total revenue rose 370% to USD 35.58 million as net loss narrowed 77% to USD 17.89 million
Reuters · 03/11 12:04
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).